## Presentations 2009

<u>Bull R.A.</u>, S. T Pham, B. Cameron, F. Luciani, A. Lloyd and P. A. White. 2009. HCV evolution during early primary infection. 16th International Symposium on Hepatitis C Virus and Related Viruses, Nice, France. Poster presentation.

<u>Bull R.A.</u>, S. T. Pham, B. Cameron, F. Luciani, A. Lloyd and P. A. White. 2009. HCV evolution during early primary infection. Australian Virology Group Meeting, Lorne, Victoria. Poster presentation.

<u>Bull R.A.</u>, S. T. Pham, B. Cameron, F. Luciani, A. Lloyd and P. A. White. 2009. Virological predictors of clearance in primary HCV infection. Australian Centre for Hepatitis Virology & HIV Virology Interest Group (ACH2) Meeting, Terrigal.

<u>Bull R.A.</u>, S. T. Pham, B. Cameron, F. Luciani, A. Lloyd and P. A. White. 2009. HCV evolution during early primary infection. 16th International Symposium on Hepatitis C Virus and Related Viruses, Nice, France. Poster presentation.

<u>Bull R.A.</u>, S. T. Pham, B. Cameron, F. Luciani, A. Lloyd and P. A. White. 2009. HCV evolution during early primary infection. Australian Virology Group Meeting, Lorne, Victoria. Poster presentation.

<u>Pham S T</u>, Grebely J., Renkin M., Hellard M., Oon A., Bull R., Lloyd AR., Ffrench RA., Mathews GV., Rawlinson WD., Dore GJ. and White PA. on behalf of the ATAHC Study Group, 2009. Hepatitis C virus superinfection and mixed infection in a community setting. Australian centre for HIV and Hepatitis Virology Research (ACH2) Annual Workshop.

<u>Pham ST.</u>, Bull R., Lloyd AR., White PA. on behalf of the HITS investigators and the UNSW Hepatitis C Vaccine Initiative, 2009. Multiple Hepatitis C virus (HCV) infections in a prisoner injecting drug users (IDU) cohort. Australian Virology Group Meeting. Poster presentation.

Marit Kramski, Rob Center, Grant Rawlin, Carly Siebentritt & <u>Damian FJ Purcell</u>. Neutralizing antibody to HIV-1 Env from hyperimmune bovine colostrum as a mucosal microbicide strategy for preventing virus transmission. AIDS Vaccine Meeting, Paris, Oct 2009.

<u>Purcell DFJ</u>, Kramski M, Rawlin G, Siebentritt C and Center R. Neutralizing antibody to HIV-1 Env from hyperimmune bovine colostrum as a mucosal microbicide strategy for preventing virus transmission. Australian Society for HIV Medicine, Brisbane, Sept. 2009.

<u>Marit Kramski</u>, Rob J. Center1, Carly Siebentritt1, Adam K. Wheatley1, Grant Rawlin2 and Damian F.J. Purcell.Potent Low-Cost Neutralising Antibodies against HIV-1 from Hyperimmune Bovine Colostrum. International Microbicide Meeting, Pittsburg, USA, May 2010.

<u>Marit Kramski</u>, Rob J. Center, Carly Siebentritt, Adam K. Wheatley, Grant Rawlin and Damian F.J. Purcell. HIV-1 Hyperimmune Bovine Colostrum with Broadly Neutralizing Activity against HIV-1. Australian Virology Group Meeting, Lorne, Dec 2009.

Marit Kramski, Rob J. Center, Carly Siebentritt, Adam K. Wheatley, Grant Rawlin and Damian F.J. Purcell. HIV-1 Hyperimmune Bovine Colostrum with Broadly Neutralizing Activity against HIV-1. ACH<sup>2</sup> meeting, Yarra Valley, VIC, June 2010.

<u>Marit Kramski</u>, Rob Center, Grant Rawlin, Carly Siebentritt Damian Purcell. Neutralising antibody to HIV-1 Env from hyperimmune bovine colostrum as a mucosal microbicide strategy for preventing virus transmission. ACH<sup>2</sup> meeting, Terrigal, June 2009.

<u>Ranasinghe C</u> et al. Co-expression of IL-13 Inhibitors - An effective method to enhance HIV-specific CD8+ T cell avidity and protective immunity. ACH<sup>2</sup> June 2010.

Ranasinghe C et al. Co-expression of IL-13 inhibitors – An effective way to enhance HIV-specific CD8+ T cell avidity and protective immunity. Mechanisms of Vaccines, Keystone Symposia series, Seattle, USA Oct 2010 –Poster presentation.

Ranasinghe C et al. Co-expression of IL-13 inhibitors: An effective way to enhance HIV-specific mucosal/systemic CD8+ T cell avidity and protective immunity. \*Conference abstract & oral presentation – Gene Based Vaccines, Cannes, France November 2010

<u>Ranasinghe C</u> et al. Can vaccines that co-express IL-13 inhibitors enhance HIV-specific mucosal & systemic CD8+ T cell immunity? ASI Perth December 2010.

<u>Ranasinghe C</u> et al. Development of vaccines to enhance HIV-specific CD8+ T cell avidity and protective immunity. \*Conference abstract & oral presentation - ACH<sup>2</sup> June 2011.

Wijesundara DK, Ramshaw IA, Jackson RJ, Tcharke TC, & Ranasinghe C. IL-4R $\alpha$  reduction following vaccinia virus infection is a feature of vaccinia-specific effector CD8<sup>+</sup> T cells. ACH<sup>2</sup> June 2011.

<u>Haran Sivakumaran</u>, Armando van der Horst, Alex J. Fulcher, Ann Apolloni, David A. Jans, David Harrich. Influencing s the stability of HIV-1 Tat as a drug target,. ACH<sup>2</sup> Workshop June 1- 3 2011 Sunshine Coast.

Trivedi S & Ranasinghe C. Elucidating the role of Interleukin-3 (IL-3) in HIV-1 prime-boost immunization. ACH<sup>2</sup> June 2011.

Ravichandran J, Jackson R & Ranasinghe C. Role of IL-17 in HIV-specific immunity: Is IL-17 involved in T cell avidity. ACH<sup>2</sup> June 2011.

<u>Smith J.</u> Characterisation of Interferon-lambda producing cells in HCV infection and the influence of polymorphisms on HCV clearance. ACH<sup>2</sup> Conference, June 2011, QLD.

Kylie Warren, <u>Ting Wei</u>, David Warrilow and David Harrich. Cellular Factors and HIV-1 Reverse Transcription. ACH<sup>2</sup> Workshop June 1- 3 2011 Sunshine Coast.

<u>White PA</u>, Pham ST Grebely J, Hellard M, Bull R, Lloyd AR, Kaldor, J, Rawlinson WD, Mathews GV, Ffrench RA, Dore GJ on behalf of the ATAHC Study Group. 2009. Hepatitis C virus superinfection in a community setting. 16th International Symposium on Hepatitis C Virus and Related Viruses, Nice, France. Poster presentation.

White PA, Grebely J, Matthews GV, Renkin M, Hellard M, Lloyd A, Rawlinson W, Dore GJ. 2008. Reinfection and Superinfection of Hepatitis C virus. 15th International Symposium on Hepatitis C Virus and Related Viruses, San Antonio, USA. Poster presentation.

White PA, Grebely J, Flynn J, Matthews GV, Renkin M, Yeung B, Rawlinson W, Kaldor J, Lloyd A, Hellard M, Ffrench R and Dore GJ, on behalf of the ATAHC Study Group. 2008. Natural history of HCV reinfection and superinfection. Viral Hepatitis - 6th Australasian Conference - Brisbane 2008.

<u>Peter A. White</u>, Melanie Renkin, Gail Matthews, Jacqueline Flynn, Jason Grebely, Pip Marks, Margaret Hellard, William Rawlinson, John Kaldor Andrew Lloyd, Rose Ffrench and Gregory J. Dore for the ATAHC Study Group. 2008. Hepatitis C virus reinfection in the Australian trial in acute hepatitis C (ATAHC). Australian Centre for HIV and Hepatitis Virology Research (ACH<sup>2</sup>) Annual Workshop.